Carboplatin
Large Cell Neuroendocrine Carcinoma
Explore 9 assets in Large Cell Neuroendocrine Carcinoma →Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
Oncology Center of Biochemical Education And Research
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06717243CT.gov Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS) | — | Recruiting | — | — | — |
NCT05652686CT.gov A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Large Cell Neuroendocrine Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Carboplatin (this asset) | Oncology Center of Biochemical Education And Research | P1/2 | CC · 47 |
| Ipilimumab | National Cancer Institute (NCI) | P2 | CCC |
| Nivolumab | National Cancer Institute (NCI) | P2 | CCC |
| Cabozantinib | National Cancer Institute (NCI) | P2 | CCC |
| Dexasone | AbbVie | P1/2 | CCC |
| [212pb]pb-mp0712 | Molecular Partners AG | P1/2 | CCC |
| [203Pb]Pb-MP0712 | Molecular Partners AG | P1/2 | CCC |
| Etoposide | Phanes Therapeutics | P1/2 | CC |
| Rhenium Re-188 P2045 | University of Maryland, Baltimore | P1/2 | CC |
+3 more in the Large Cell Neuroendocrine Carcinoma cohort
Other indications for Carboplatin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lung Large Cell Carcinoma | — | P4 | A · 80 |
| Primary Peritoneal Carcinoma | — | P3 | BBB · 76 |
| Non-Small Cell Squamous Lung Carcinoma | — | P3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Carboplatin in Large Cell Neuroendocrine Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 10, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/carboplatin-large-cell-neuroendocrine-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →